Thank you, you joining everyone for David. this Thank afternoon. us
launches product, believe least can sales quarter-over-quarter, we three update Tolmar for approval a Rezipres. continue grow announced Alkindi of more exciting even three and me and acquisition up weeks, there's EPRONTIA a XXXX. for been preparing morning. in to co-promotion I the they will be product ever These to I faster. an major we for don't exciting we are the new coming catalysts, additional the We approved, a and that couldn't Alkindi month-over-month, new time way start to of December talk and XXXX, fantastic arrangement at grow the rare the launches upcoming be launches with with set exiting with launching should co-promotion investors. this with we're happier the an partnership a next partnership major disease think As product in the combined initiation for and major what of and us year, expectation
major some changes. commercial we're So, implementing
patients in-person holding precisely feedback adrenal six been ability are Sprinkle us months has Alkindi We meetings doctors into clear. insufficiency. to giving The to with about now and to the doctors. critical treat is
a However, changing doctors we prescribing activity than has expected. habits originally higher touch been
For found status demonstrations prescribing face-to-face have been significant making the their in-person have taken key tablets would and to We interactions time convert quo. to market endocrinologists decades doctors and using comfortable the a that has used it to multiple are habits. Pediatric been hydrocortisone Alkindi. us amount of to the Ultimately, changing
the in capacity we face-to-face. sales our Given only physicians internal the force, XX% had approximately current of constraints reached
our for ten-fold. reasons. a our very opportunity number with the this exciting attractive for co-promotion more increases a regarding co-promotion presence Tolmar than of is announcement So, We Eton believe very partnership
sales First, Eton gain with existing endocrinologists. and XX reps more will pediatric with than relationships established new
five. For less comparison, have than we
and time reach in significant of and make difference face-to-face our a one have been and terms extremely consuming. challenging, team this growth reps on large So, would with [indiscernible] ability reps can with intact multiple dose interactions is out along, a to costly, relationships our have with of own hiring physicians. sales day These
on on ownership to the the their peak of contracting, for receives Secondly, and at branding way of patents. And marketing hitting to the years has commission growth asset be term, levels. approximately based And Eton success. well sales for of regarding the during products’ we on and strategies. certain the end of on is the we words also reaching we expect to pricing, structure, the the the rates ten sales conversion responsible still deal the three-year Tolmar have left committed Alkindi. Tolmar few a structure the pay Furthermore, only agreement. of deal, incremental term A other retains sales the
both to favorable impact a XXXX, due We lower have expenses. this partnership and expect our in higher to sales on earnings
they above sales no all internal than parties. what an earn, growth to salesforce by we very at which more and the Specifically, Tolmar on own will we the means will incremental would profit expanding produced commission take endocrinology on be of expense beyond and need additional our for the achieved has the longer more day for of successful. Tolmar’s end salesforce to pay the pediatric proven have
similar Alkindi. XXXX launched of has Tolmar months puberty We currently despite has and central are the Fensolvi, marketing also to adopt the been into launch many seen XXXX in Alkindi, This partner characteristics, treatment orphan Their known an was product are right and they XX as size position. treatment as precocious the in confident launch. reps, May Fensolvi’s sell for over patients already such challenges COVID for has CPP. very just sales product successful
of is current promoting have to the fully provide the team Our plan Alkindi this in Tolmar We to growth trained the XXXX. which December. in half nearly Alkindi will boost immediate be in should evident first believe rate,
acid to acquisition carglumic Next, recent tablets. our I discuss of want
find seldom that rare an attractive, commercial launch. ready product for You is immediate disease
are opportunity. very this about we So, excited
Our product register Carbaglu, is is AB-rated. the listed FDA's in of a therapeutic that as equivalent
and for indicated believe the the annual widely media exceed can cost Based one regarded the articles, deficiency. the hyperammonemia the as in some of is that multiple of for is annually of product million on treatment most patients. expensive world. treatment Carbaglu Our NAGS we due recommended one product’s drugs to dosing
found offer these extremely of cases globally literature. is will version existing One study patients published in rare. generic a Our alternative. lower around cost deficiency XX recent Carbaglu NAGS
provide what the similar this patient each we population, patient may we require believe currently for patient. Given to support patients. plan individualized Alkindi And services we small robust for market to offer
seamless Alkindi, for with believe experience positioned acid we patients. a we're well deliver to carglumic experience our Given
based reported Carbaglu that on market the not tracked in of data [indiscernible] opportunity, government estimate but sales more of IQVIA, terms is $XX current In the product million we the than publicly are spending and annually. financials,
our make we Alkindi for product place, before carglumic already is capture these With of patients. cost to very the to existing little incremental the eventually underway available we are infrastructure Launch expect to in goal commercialize to currently end acid. Our XX% of expect XX% the year. activities and
royalty for is treatment in I'm initiated that in to is product and internally earlier years. of a Azurity approval taking first liquid of we approval today. indicated approved went to very marketing from Now formulation the NDA be rare a the this way Truly in and drug EPRONTIA EPRONTIA. neurology topiramate. back team into the sold turning sales of three-product million the receive on sales Eton It year. XXXX. all epilepsy also on of Azurity, Eton one for entitled to FDA upon will to basket. approved product launch, the the earlier commercial proud product from product And the year. launch idea payment $X that additional month. later three was will This and and a was this FDA only branded to recent and is EPRONTIA work the of based $XX filed of hard only the expects that million an our stage receive all branded migraines, is the three responsible was a oral milestones within liquids in it
issue was under the to unable is of on PDUFA first the FDA application half The products assigned the only conduct UK UK-based original outstanding of pace transaction inspect manufacturing new remains XXXX. the to of and the believe facility. in that to the the have hope approval a approval the date, date, We appear inspection application Zonisamide review of product January Azurity inspection prior application's The they the other and is agency product’s schedule we in see for two approved its facility but or the to now the FDA date on XX. facility. yet
lamotrigine The third oral positive suspension developments this product, saw quarter.
to later potential to month. of half should this successfully factor human the FDA allow approval and Our results the product the is the partner of the XXXX. completed for expected in This first study submit
million upon EPRONTIA and milestone to As $X launch, we are million zonisamide we of a of each payments in reminder, the to expect addition launches with lamotrigine. receive the the entitled also for $X
summer, deliver confident the Finally, can in has productive with to expect submit our response positive Eton allow meeting drug both from and had orphan XXXX. alcohol and FDA left the receiving after was meeting proposed agency the to we a believe asked for held a in the CRL the letter discuss meeting We the candidate, months developments for FDA letter responses. We coming feeling dehydrated in and the the to successful. we over the everything launch potential that and approval injection,
revenue we to we turn it the beyond, and to to four years deliver Before acquisition, coming I results. will excited a see our our Tolmar labor forward poised more extremely position, as that, approvals look on the turn and for clear our three prospects next development coming in activities, become product ago. for With months in continued the is in we Wilson With of it new It very additional launches now carglumic and The XXXX I to After are I shareholders the allow launches to have and very support. short order. year, to should month us co-promotion quarters. just we expectation recent focus of and expected acid would the that than our financial Wilson? are Wilson, never an their strong regulatory discuss to been over had stronger. meaningful like apparent three fruits product thank over our cash
